Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 30 articles:
HTML format



Single Articles


    July 2022
  1. PIVOT X
    Pembrolizumab in the Treatment of Breast Cancer.
    N Engl J Med. 2022;387:273-274.
    PubMed    


  2. CORTES J, Rugo HS, Cescon DW, Im SA, et al
    Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:217-226.
    PubMed     Abstract available


  3. HURVITZ SA
    DESTINY-Changing Results for Advanced Breast Cancer.
    N Engl J Med. 2022;387:75-76.
    PubMed    


    June 2022
  4. JATOI I, Sung H, Jemal A
    The Emergence of the Racial Disparity in U.S. Breast-Cancer Mortality.
    N Engl J Med. 2022;386:2349-2352.
    PubMed    


  5. CORTES J, Im SA, Cathcart J
    Trastuzumab Deruxtecan for Breast Cancer. Reply.
    N Engl J Med. 2022;386:2347.
    PubMed    


  6. ZHENG F, Du F, Yuan P
    Trastuzumab Deruxtecan for Breast Cancer.
    N Engl J Med. 2022;386:2346-2347.
    PubMed    


  7. MODI S, Jacot W, Yamashita T, Sohn J, et al
    Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
    N Engl J Med. 2022 Jun 5. doi: 10.1056/NEJMoa2203690.
    PubMed     Abstract available


    May 2022
  8. SCHMID P, Cortes J, Dent R
    Pembrolizumab in Early Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;386:1771-1772.
    PubMed    


  9. GANGULY S, Gogia A
    Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:1771.
    PubMed    


    March 2022
  10. CORTES J, Kim SB, Chung WP, Im SA, et al
    Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    N Engl J Med. 2022;386:1143-1154.
    PubMed     Abstract available


  11. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
    N Engl J Med. 2022;386:942-950.
    PubMed     Abstract available


    February 2022
  12. SCHMID P, Cortes J, Dent R, Pusztai L, et al
    Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:556-567.
    PubMed     Abstract available


    December 2021
  13. SHARMA V, Kumar A
    Carcinoma en Cuirasse.
    N Engl J Med. 2021;385:2562.
    PubMed    


  14. KALINSKY K, Barlow WE, Gralow JR, Meric-Bernstam F, et al
    21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
    N Engl J Med. 2021;385:2336-2347.
    PubMed     Abstract available


    October 2021
  15. TUTT ANJ, Garber JE, Geyer CE Jr
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
    N Engl J Med. 2021;385:1440.
    PubMed    


  16. HOSHI A, Bando H, Sekine I
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439-1440.
    PubMed    


  17. NOZAWA K, Yoshimura A, Iwata H
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439.
    PubMed    


    September 2021
  18. BOSE R, Ma CX
    Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.
    N Engl J Med. 2021;385:1241-1243.
    PubMed    


    July 2021
  19. GOODWIN PJ
    Extended Aromatase Inhibitors in Hormone-Receptor-Positive Breast Cancer.
    N Engl J Med. 2021;385:462-463.
    PubMed    


  20. GNANT M, Fitzal F, Rinnerthaler G, Steger GG, et al
    Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
    N Engl J Med. 2021;385:395-405.
    PubMed     Abstract available


  21. BARDIA A, Hurvitz SA, Rugo HS
    Sacituzumab Govitecan in Metastatic Breast Cancer. Reply.
    N Engl J Med. 2021;385:e12.
    PubMed    


  22. GANGULY S, Gogia A
    Sacituzumab Govitecan in Metastatic Breast Cancer.
    N Engl J Med. 2021;385:e12.
    PubMed    


    June 2021
  23. TUTT ANJ, Garber JE, Kaufman B, Viale G, et al
    Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
    N Engl J Med. 2021 Jun 3. doi: 10.1056/NEJMoa2105215.
    PubMed     Abstract available


    April 2021
  24. BARDIA A, Hurvitz SA, Tolaney SM, Loirat D, et al
    Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    N Engl J Med. 2021;384:1529-1541.
    PubMed     Abstract available


    March 2021
  25. BURSTEIN HJ
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply.
    N Engl J Med. 2021;384:1176-1177.
    PubMed    


  26. COPUR MS
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    N Engl J Med. 2021;384:1176.
    PubMed    


    January 2021
  27. DORLING L, Carvalho S, Allen J, Gonzalez-Neira A, et al
    Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMoa1913948.
    PubMed     Abstract available


  28. NAROD SA
    Which Genes for Hereditary Breast Cancer?
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMe2035083.
    PubMed    


  29. HU C, Hart SN, Gnanaolivu R, Huang H, et al
    A Population-Based Study of Genes Previously Implicated in Breast Cancer.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMoa2005936.
    PubMed     Abstract available


    December 2020
  30. BURSTEIN HJ
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    N Engl J Med. 2020;383:2557-2570.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: